Fig. 6From: Pretreatment risk management of a novel nomogram model for prediction of thoracoabdominal extrahepatic metastasis in primary hepatic carcinomaDecision curve analysis for classification of different risk population. The net benefit was calculated by subtracting the proportion of false positive from the proportion of true positive in all patients, weighting with the relative harm driven by false positive. Weighing the net benefit, threshold probability was classified for three-independent risk population, which was < 19.9%, 19.9–71.8% and > 71.8%, respectivelyBack to article page